Clinical Trials
12 trialsNCT05442515 2026-05-27
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07302347 2026-05-26
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03223610 2026-05-22
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT03789097 2026-05-22
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT05826535 2026-05-20
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT06137144 2026-05-19
PRIMAVERA
AstraZeneca
Phase 1/2 Recruiting
NCT02332668 2026-05-18
MK-3475-051
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05683171 2026-05-15
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06678659 2026-05-08
DAHLIA
Recursion Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT05896163 2026-05-06
MAPtivate-6
Pfizer
Phase 1/2 Terminated
NCT04870944 2026-05-05
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT07249905 2026-05-04
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting